WO2019117444A1 - 전분화능 줄기세포를 이용한 면역세포 분화 - Google Patents
전분화능 줄기세포를 이용한 면역세포 분화 Download PDFInfo
- Publication number
- WO2019117444A1 WO2019117444A1 PCT/KR2018/012065 KR2018012065W WO2019117444A1 WO 2019117444 A1 WO2019117444 A1 WO 2019117444A1 KR 2018012065 W KR2018012065 W KR 2018012065W WO 2019117444 A1 WO2019117444 A1 WO 2019117444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- differentiation
- cells
- macrophages
- hematopoietic stem
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 113
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 24
- 210000002540 macrophage Anatomy 0.000 claims abstract description 121
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 65
- 210000004027 cell Anatomy 0.000 claims abstract description 59
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims abstract description 44
- 230000001939 inductive effect Effects 0.000 claims abstract description 41
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 34
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 210000000130 stem cell Anatomy 0.000 claims description 53
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 41
- 230000006698 induction Effects 0.000 claims description 28
- 102000004889 Interleukin-6 Human genes 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 24
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 24
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 24
- 102000036693 Thrombopoietin Human genes 0.000 claims description 21
- 108010041111 Thrombopoietin Proteins 0.000 claims description 21
- 230000024245 cell differentiation Effects 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 20
- 108010002386 Interleukin-3 Proteins 0.000 claims description 19
- 229940076264 interleukin-3 Drugs 0.000 claims description 15
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 14
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims description 6
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 108010023082 activin A Proteins 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 102000000646 Interleukin-3 Human genes 0.000 claims 6
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 abstract description 10
- 108090000695 Cytokines Proteins 0.000 abstract description 10
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 abstract 3
- 239000002609 medium Substances 0.000 description 28
- 102100039064 Interleukin-3 Human genes 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 8
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 7
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- -1 CDDO methyl ester compound Chemical class 0.000 description 5
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000606646 Anaplasma Species 0.000 description 1
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 1
- TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101100127285 Drosophila melanogaster unc-104 gene Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 208000022506 anaerobic bacteria infectious disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2539/00—Supports and/or coatings for cell culture characterised by properties
Definitions
- the present invention relates to a method for inducing differentiation of hematopoietic stem cells or macrophages from pre-differentiating stem cells and a composition for inducing differentiation thereof.
- Differentiated hematopoietic stem cells can be further differentiated into myeloid cells such as macrophages, neutrophils, and monocytes.
- the differentiation induction method of the present invention is characterized in that direct differentiation is performed without forming an embryonic body (cell aggregate) in the step of differentiating macrophages from pre-differentiating stem cells.
- stepwise treatment of the additives for inducing differentiation a method of excluding a composition for inhibiting differentiation, a method of using APEL as a basic medium for differentiation, etc., an excellent yield is obtained as compared with the known methods.
- Precipitating stem cells are undifferentiated stem cells that can differentiate into all the cells that make up the human body. Since the establishment of human embryonic stem cells (hESCs) in the late 1990s, the field of stem cell research that has been launched in earnest has been a breakthrough since the breakthrough of the production of induced pluripotent stem cells (iPSCs) in the mid-2000s have. Recently, human cell somatic cell nuclear transfer ESCs (hSCNT-ESCs) have been successfully established and stem cell research is becoming more active.
- Congenital immune response is the first defense to protect our body from pathogens invading from the outside. It is also called nonspecific immunity. Congenital immune responses include neutrophils, monocytes, macrophages, and innate immune responses are initiated regardless of the pathogen or the presence of infection.
- Macrophages are the cells responsible for the innate immune response and are present in the whole body. Most macrophages are adherent. They are dust cells, microglial cells, Cooper cells, and Langerhans cells. When they recognize an antigen, they feed it, they secrete toxins and destroy them, they transmit an antigen to lymphocytes and cause an immune response do. Macrophages may be present as monocytes that are not differentiated into some blood. Monocytes may be differentiated into dendritic cells or macrophages as needed. Various signal substances are involved in the differentiation of macrophages.
- the desired cells can be obtained through differentiation induction of the pluripotent stem cells.
- differentiation into immune cells can be utilized in various diseases diagnosis or drug screening methods. Accordingly, there is a need for a novel stem cell differentiation inducing method and a composition for inducing differentiation that can increase the differentiation efficiency and yield of the final cell.
- the inventors of the present invention have developed various protocols for the development of a method for inducing the differentiation of hematopoietic stem cells or macrophages with high efficiency by improving the previously developed protocol, changing the composition of the cytokine, The present inventors have completed the present invention by confirming a method of inducing successful differentiation from pre-differentiating stem cells through hematopoietic stem cells into macrophages.
- the inventors of the present invention confirmed that the macrophages produced by the induction method of the present invention have a very high similarity with human macrophages, and thus can utilize them in various ways.
- BMP4 bone morphogenetic protein 4
- M-CSF macrophage colony stimulating factor
- Another object of the present invention is to provide a composition for inducing myeloid stem cell-derived myeloid stem cells and macrophage differentiation comprising osteogenic protein 4 (BMP4) and macrophage colony stimulating factor (M-CSF) .
- BMP4 osteogenic protein 4
- M-CSF macrophage colony stimulating factor
- the present invention provides a method for culturing stem cells comprising the steps of: maintaining pre-differentiating stem cells cultured in mTeSR1 or mTeSR8 basal medium in a dish coated with vitronectin or matrigel; Transferring to a hematopoietic stem cell differentiation induction medium containing BMP4; Treating the precursor stem cells with VEGF and SCF and culturing them, and then treating the signal material to induce myeloid type hematopoietic stem cell differentiation; And transferring the differentiated hematopoietic stem cells to a macrophage differentiation induction medium containing M-CSF and culturing the cells at a density of 10 5 cells / cm 2 or more.
- the present invention provides a composition for inducing differentiation stem cell-derived macrophage differentiation comprising osteogenic protein 4 (BMP4) and macrophage colony stimulating factor (M-CSF) on the basis of APEL medium.
- BMP4 osteogenic protein 4
- M-CSF macrophage colony stimulating factor
- the present invention provides mesoderm induction treatment of bone morphogenetic protein 4 (BMP4) only at high concentration for 2 days, low concentration for 2 days, and cytotoxicity of VEGF and SCF
- BMP4 bone morphogenetic protein 4
- the present invention also provides a method for treating cyanogen only with hematopoietic stem cells.
- bFGF and the like which interfere with differentiation are excluded.
- CDDO methyl ester CDDO metyl ester
- CDDO metyl ester is further added to further enhance the yield of myeloid hematopoietic progenitor cells.
- the present invention relates to a method for obtaining pure myeloid hematopoietic progenitor cells by treating cytokines of IL3, IL-6, FLT3 and TPO to mature the differentiated hematopoietic stem cells into myeloid hematopoietic progenitor cells. In this step, M-CSF is not treated. This is an efficient differentiation method in that the yield of pure myeloid hematopoietic progenitor cells can be increased as compared with the conventional method.
- the present invention relates to a method for inducing differentiation, which comprises inducing macrophage differentiation by treating only macrophage-colony stimulating factor (M-CSF) with myeloid hematopoietic progenitor cells.
- M-CSF macrophage-colony stimulating factor
- the method of inducing differentiation of the present invention is characterized by high efficiency of differentiation and direct differentiation without the step of embryonic body formation, so that the yield of differentiated cells is highest by several tens of times compared to the conventional method.
- the macrophage differentiated according to the differentiation induction method of the present invention has a wide range of applications in various fields where the number of cells is large.
- the method of inducing macrophage differentiation comprises inducing differentiation into myeloid haematopoietic stem cells from pre-differentiating stem cells and then inducing differentiation into macrophages, wherein bone morphogenetic protein 4 (BMP4) and macrophage colony stimulating
- BMP4 bone morphogenetic protein 4
- M-CSF factor
- a composition for inducing differentiation comprising the signal substance, which is characterized by a simple step of differentiation, a small number of cytokines, And the yield of differentiated cells is high.
- FIG. 1 is a schematic illustration of a method for inducing differentiation of myeloid type HSC according to the present invention, and is a hematopoietic cell differentiation protocol showing four types of HSC differentiation basal medium.
- FIG. 2 shows fluorescence-labeled CD34 + CD45 +, a marker specifically expressed in hematopoietic stem cells, in order to confirm the hematopoietic differentiation according to each basic medium.
- FIG. 3 is a graph showing the yield of CD34 + CD45 + hematopoietic stem cells (HSPC) distinguished by marker expression as a quantitative cell number, which means the number of CD34 + CD45 + hematopoietic stem cells produced from 5 colonies.
- HSPC hematopoietic stem cells
- FIG. 4 shows the yields of CD34 + CD45 + hematopoietic stem cells (HSPC) in the case of treatment with compound CDDO methyl ester and in case of treatment without inducing hematopoietic stem cell differentiation.
- HSPC hematopoietic stem cells
- FIG. 5 shows the ability of the hematopoietic stem cells produced according to the basic medium of the present invention to colonize hematopoietic cells.
- GM Gramulocyte Macrophage-colony forming unit
- the hematopoietic stem cell differentiation method of the present invention based on the APEL basic medium has the ability to differentiate into myeloid cells.
- FIG. 6 is a graphical representation of the method of inducing macrophage differentiation according to the present invention, and is about the whole differentiation induction protocol.
- step 7 is a schematic diagram comparing with a known protocol. Compared to the existing protocol, bFGF was removed in step 2, and SCF and M-CSF were removed in step 3 and IL6 was added. In step 4, FL3 and GM-CSF were removed. The yield of macrophages increased about 3.8 times on D28 days compared to the known protocols, and increased 100 times when the amounts produced until the end were compared. This indicates that the present invention is a method of increasing the yield while reducing the number of cytokines.
- FIG. 8 shows the production efficiency of macrophages according to the present invention, and shows the expression of macrophage-specific marker when the floating hematopoietic stem cells differentiate into macrophages.
- Figure 9 quantitatively represents the percentage (%) of cells expressing macrophage specific markers, i.e., purity.
- Fig. 10 quantitatively shows the number of macrophages produced from 20 colonies of pre-differentiating stem cells.
- FIG. 11 shows quantitative analysis of the percentage of cells that fluoresce by flow cytometry as a result of confirming the macroscopic action of the cells through opsonized beads, in order to identify macrophages with differentiation.
- FIG. 12 shows the results of analysis of the similarity between differentiated macrophages and human-derived macrophages using a gene expression pattern, which shows that the differentiated macrophages (iMAC) of the present invention, human monocyte-derived macrophages (hMDM) , And human macrophage cell line (Thp-1) were statistically analyzed by Principal Component Analysis (PCA).
- PCA Principal Component Analysis
- Fig. 13 shows the results of the possibility of infection of differentiated macrophages with viruses and bacteria. After differentiated macrophages were infected with H3N2 cold virus or A. phagocytophilum bacteria, macrophages were stained with cytospin method and observed with a microscope will be.
- FIG. 14 is a TEM (transmission electron microscope) microscopic observation of the infected macrophages showing the infected viruses and bacteria in the cells.
- Figure 15 shows that ROS increased after infection with a virus or bacteria in differentiated macrophages.
- Figure 16 shows that the secretion of inflammatory cytokines increased after infection of the differentiated macrophages with virus or bacteria.
- FIG. 17 is a result showing the possibility of infecting the differentiated macrophages with Mycobacterium tuberculosis. After infection, the infectivity of Mycoplasma Tuberculosis was observed when the cells were treated with MOI concentrations of 0 to 20, Of the total amount.
- the present inventors have studied a method for differentiating the pluripotent stem cells into hematopoietic cells or macrophages, and have completed the method of the present invention, which uses a small number of cytokines and has high differentiation efficiency and macrophage yield.
- the method of inducing macrophage differentiation comprises culturing a pluripotent stem cell in a mTeSR1 or mTeSR8 basal medium and keeping it in an undifferentiated state in a matrigel or a vitronectin coating dish; Maintaining the total pluripotent stem cells cultured in said basal medium at 5 colonies or less per 35 pidish; Culturing the BMP4 alone at a high concentration for 2 days and at a low concentration for 2 days based on the APEL culture medium and transferring it to the induction medium for hematopoietic stem cell differentiation; Treating the pluripotent stem cells with VEGF and SCF and culturing them on an APEL culture medium, and then treating further signal substances to induce differentiation into hematopoietic stem cells; And transferring the differentiated hematopoietic stem cells to a macrophage differentiation induction medium containing M-CSF based on an RPMI culture medium and culturing
- BMP Breast Morphogenetic Protein
- TGF- ⁇ Transforming Growth Factor ⁇
- BMP is known to play a role in promoting the differentiation of stem cells into bone cells or chondrocytes in mammals (Jiwang Zhang, Linheng Li, BMP signaling and stem cell regulation (2005) Developmental Biology 284 1-11).
- Bone morphogenetic BMPs are the first signaling molecules when stem cells differentiate into osteoblasts during osteogenesis, and BMP2, 4, and 7 are mainly involved in bone formation during fracture healing M. Egerman, CA Lill, and K. Criesbeck, Effects of BMP-2 genetransfer on bone healing in sheep (2006) Gene Therapy, Vol.13, No. 17, 1290-1299).
- BMP4 and 6 have been reported to have the function of inducing bone and cartilage (Morone MA, Boden SD, Hair G et al. Gene expression during autograft lumbar spine fusion and the effect of bone morphogenetic protein 2 (1998) Clin Orthop (351) 252; Gruber R, Kandler B. Fuerst G et al, Porcine sinus mucosa cells in response to bone morphogenic protein BMP-6 and BMP-7 with increased osteogenic differentiation in vitro (2004) Clin Oral Implants Res 15 5) 575-580).
- the present invention relates to a method for the proliferation and differentiation of osteogenic protein 4 (BMP4), which is one of the osteogenic proteins, in order to rapidly differentiate pre-differentiating stem cells or degenerated stem cells cultured in an undifferentiated state into mesodermal cells .
- BMP4 osteogenic protein 4
- the BMP4 is a protein involved in a signal transduction pathway leading to mesenchymal stem cells, and in order to induce the differentiation of the pluripotent stem cells cultured in the basic medium into hematopoietic stem cells, Followed by transferring to a differentiation induction medium and culturing.
- the BMP4 may be treated at a concentration of 20 to 100 ng / ml, but is not limited thereto. When treated at 20 ng / ml or less, induction of differentiation into mesodermal lobes is not performed well, and when treated at a concentration of 100 ng / ml or more for a long period of time, the efficiency is inferior in terms of economy.
- the present invention may include a method of culturing the BMP4 at a concentration of 100 ng / ml initially, then culturing for 2 days, and further culturing for 2 days at a concentration of 20 ng / ml. It is preferable that the present invention is cultured by treating BMP4 for 4 days.
- the present invention may include a method for further culturing the CDDO methyl ester compound by treating the BMP4 treatment step. Further treatment of the CDDO methyl ester compound can improve the yield of hematopoietic stem cells by more than three-fold.
- the present invention includes a step of treating various additional signal substances in order to differentiate mesodermal stem cells induced into mesenchymal stem cells into myeloid hematopoietic stem cells on a differentiation inducing medium.
- the signal materials usable in the present invention include vascular endothelial growth factor (VEGF), stem cell factor (SCF), thrombopoietin (TPO), interleukin-6, IL-6), interleukin-3 (IL-3), and FMS-like tyrosine kinase 3 (Flt3).
- VEGF vascular endothelial growth factor
- SCF stem cell factor
- TPO thrombopoietin
- IL-6 interleukin-6
- IL-3 interleukin-3
- Flt3 FMS-like tyrosine kinase 3
- the signal substance may be sequentially included in the induction medium.
- the method comprises culturing VEGF and SCF for 2 days, further culturing TPO, IL6, IL3 and Flt3 for 10 days or more, and differentiating them into myeloid hematopoietic stem cells.
- VEGF and SCF play a role in promoting hemangioblast.
- TPO, IL6, IL3 and Flt3, which are processed sequentially, are not only differentiated But it helps to play a role in the self-proliferation of hematopoietic stem cells.
- the signal substances are essential substances for differentiation of hematopoietic stem cells. It is preferable that the signal materials are sequentially processed in order to differentiate into mesodermal cells and differentiate into hematopoietic stem cells.
- the hematopoietic stem cells of the present invention have characteristics as GMP (Granulocyte-Macrophage Progenitor), which is an intermediate stage in differentiation into macrophages, magakaryocytes or neutrophils.
- GMP Gramulocyte-Macrophage Progenitor
- the induction of this differentiation is closely influenced by the kind of the signal substance and the order of treatment. GMP production occurs most often when the differentiation is induced under the above conditions.
- the basic medium used in the present invention may be APEL, and APEL (Albumin Polyvinylalcohol Essential Lipids) is a medium in which animal serum is not contained and animal-derived ingredients are not contained. Andrew G. Elefanty firstly embryonic stem cells (Nature protocol 3, 768-776, 2018).
- the APEL comprises the composition of Table 1 below.
- the present invention includes a step of differentiating macrophages from the differentiated hematopoietic stem cells.
- macrophage colony-stimulating factor M-CSF
- M-CSF macrophage colony-stimulating factor
- the cells induced and differentiated into hematopoietic stem cells are maintained and cultured as much as possible, and then treated with M-CSF to differentiate into macrophages.
- the GMP-differentiated cells are treated with M-CSF.
- One embodiment of the present invention comprises treating M-CSF and IL-3 together or sequentially.
- IL-3 When IL-3 is first treated, the differentiation rate of myeloid hematopoietic stem cells can be increased. After that, M-CSF treatment results in generation of macrophages with higher purity since myeloid hematopoietic stem cells differentiate into macrophages And has a much higher yield compared to previously known differentiation methods.
- the sequential treatment method in comparison with the method of simultaneously treating M-CSF and IL-3 has a higher yield.
- M-CSF can be initially treated at a concentration of 100 ng / ml and reduced to a concentration of 20 ng / ml after a certain period of time.
- the hematopoietic stem cells are induced to have the characteristics as GMP, and as much GMP as possible is obtained before treatment with M-CSF, Since it can be differentiated into phagocytes, the yield of macrophages can be increased.
- the present invention relates to a method for the treatment of hematopoietic stem cell differentiation, comprising the steps of: 1) culturing pre-differentiating stem cells in hematopoietic stem cell differentiation induction medium containing BMP4; 2) treating the pluripotent stem cells with VEGF and SCF; And 3) treating the pluripotent stem cells with TPO, IL-6, IL-3 and Flt3.
- step 1) of the differentiation induction method of the present invention any one or more of Activin A, bFGF, and TGFb is not further included, so that the number of cytokines to be used can be reduced.
- BMP4 is preferably contained at a concentration of 20 to 100 ng / ml, and it may be preferable to treat BMP4 at a low concentration initially and then once at a high concentration.
- the hematopoietic stem cell differentiation inducing medium is preferably APEL (Albumin Polyvinylalcohol Essential Lipids).
- the present invention relates to a method for the treatment of hematopoietic stem cell differentiation, comprising the steps of: 1) culturing pre-differentiating stem cells in hematopoietic stem cell differentiation induction medium containing BMP4; 2) treating the pluripotent stem cells with VEGF and SCF; 3) inducing hematopoietic stem cell differentiation by treating TPO, IL-6, IL-3 and Flt3 to the pluripotent stem cells; And 4) adding the differentiated hematopoietic stem cells to a macrophage differentiation induction medium containing M-CSF and culturing the same.
- step 4 it is preferable that the cell density is maintained at 1 ⁇ 10 5 cells / cm 2 or more during macrophage culture.
- the present invention relates to hematopoietic stem cells differentiated from pre-differentiating stem cells by the differentiation induction method.
- the present invention relates to macrophages induced to differentiate from pre-differentiating stem cells by the differentiation induction method.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF), stem cell factor (SCF), thrombopoietin (TPO) IL-6, interleukin-6, IL-6, interleukin-3, IL-3, CDDO methyl ester and FMS-like tyrosine kinase 3
- BMP4 bone morphogenetic protein 4
- VEGF vascular endothelial growth factor
- SCF stem cell factor
- TPO thrombopoietin
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF), stem cell factor (SCF), thrombopoietin (TPO) , Interleukin-6, IL-6, interleukin-3, IL-3, FMS-like tyrosine kinase 3, Flt3, and macrophage colony stimulating factor Colony-Stimulating Factor (M-CSF).
- BMP4 bone morphogenetic protein 4
- VEGF vascular endothelial growth factor
- SCF stem cell factor
- TPO thrombopoietin
- Interleukin-6 Interleukin-6
- IL-6 interleukin-3
- IL-3 interleukin-3
- FMS-like tyrosine kinase 3 Flt3
- M-CSF macrophage colony stimulating factor Colony-Stimulating Factor
- " pre-differentiating stem cell " is a stem cell capable of differentiation, and is a stem cell capable of differentiating into endoderm, mesoderm, ectodermal cell or tissue. But are not limited to, human embryonic stem cells, degenerated stem cells.
- the term " mesodermal cell " in the present invention refers to a cell that is induced by signaling molecule elements that regulate differentiation of stem cells, in particular by the BMP4 signaling pathway.
- the mesodermal cells of the present invention may include mesodermal cells differentiated by BMP4, and may include cells differentiated into hematopoietic mesoderm through mesodermal cells.
- " hematopoietic stem cell " is a hematopoietic cell that is potentially differentiable as a major constituent of blood, and is also referred to as " hematopoietic stem cell ".
- Hematopoietic cells can be divided into the cells generated in the fetal liver of the developmental stage, the cells generated in the yolk sac, and the cells produced in the postnatal bone marrow, and are differentiated into lymphoid cells and myeloid cells.
- the hematopoietic stem cells of the present invention can be differentiated into macrophages.
- the term " macrophage " in the present invention is responsible for congenital immunity, and it exists in the form of monocytes in the blood, and can be differentiated into dendritic cells or macrophages. Macrophages play a role in the removal of bacteria and viruses, which are manifested by phagocytosis.
- the macrophages differentiated through the differentiation induction process of the present invention can be used for a virus or a bacterial infection study model.
- " differentiation " in the present invention means a process in which an unspecific cell develops into a specific cell, and in particular, includes a process of developing from a stem cell to a specific cell.
- embryonic stem cells and degenerated stem cells are used as cells having differentiation ability, and the embryonic stem cells and dedifferentiated stem cells can finally be differentiated into macrophages through mesodermal cells and hematopoietic stem cells.
- the term " signal substance " in the present invention is a concept including all of signal proteins, cytokines, and catalysts involved in the differentiation of pluripotent stem cells.
- the present invention relates to a pharmaceutical composition comprising a bone morphogenetic protein (BMP), a macrophage colony stimulating factor (M-CSF), a vascular endothelial growth factor (VEGF), a stem cell factor (SCF), a platelet growth factor (TPO) IL-3 and Flt3.
- BMP bone morphogenetic protein
- M-CSF macrophage colony stimulating factor
- VEGF vascular endothelial growth factor
- SCF stem cell factor
- TPO platelet growth factor
- the CDDO methyl ester is used as an Nrf2 activator in the presence of 2-cyano-3,12-dioxooleana-1,9 (11) -diene-28-oxic acid methyl ester (2-cyano- dioxoleane-1,9 (11) -dien-28-oic acid methyl ester) compound.
- the CDDO methyl ester compound can be treated with BMP4 for 4 days to increase the differentiation efficiency of hematopoietic stem cells.
- VEGF and SCF were then treated to differentiate mesenchymal cells into hemangioblasts, followed by IL-3, IL-6, TPO and Flt3 to induce differentiation into hematopoietic stem cells.
- the reason why the signal material is not treated at the same time is to increase the differentiation efficiency and purity.
- the differentiation protocol is shown in detail in FIG.
- CD34 + CD45 + is a marker specifically expressed in hematopoietic stem cells.
- the mesoderm differentiated from pre-differentiation stem cells was induced to differentiate into hematopoietic stem cells. To confirm this, the expression level of the marker specifically expressed in hematopoietic stem cells was measured.
- the differentiated cells were monolayered and reacted with the fluorescently labeled antibodies CD34 and CD45.
- FACs flow cytomery
- FIGS. 2 and 3 The results are shown in FIGS. 2 and 3 .
- CD34 + CD45 + was each positive, indicating that the differentiation into hematopoietic stem cells progressed.
- the colony forming assay was performed to confirm the ability of the hematopoietic stem cells to differentiate into hematopoietic cells. The results are shown in FIG. 5, and it was confirmed that most GM colonies were formed (granulocyte-macrophage). As shown in FIG. 5, it can be seen that the hematopoietic stem cells produced in Example 1 are myeloid hematopoietic stem cells.
- the hematopoietic stem cells were collected, transferred to a fresh 60-fold dish (coated cell culture dish), and treated with 100 ng / ml of M-CSF alone to induce differentiation into macrophages.
- RPMI1640 was used as the primary medium, and 10% FBS was added. After 10 days of culture, they were subcultured at a ratio of 1: 2. At this time, the density of the cells is very important, and it is necessary to maintain the cells at 10 5 cells / cm 2 or more on the plate to increase the yield of macrophages. At this time, the concentration of M-CSF can be 20 to 100 ng / ml.
- the differentiation protocol is shown in detail in FIG.
- Differentiated macrophages were cultured in medium containing RPMI1640 medium and 10% FBS, and the amount of production was increased during orbital shaking during culture
- CD14, CD11b, and CD86 are markers specifically expressed in macrophages.
- the differentiated hematopoietic stem cells were induced to differentiate into macrophages, and the expression level of the markers was measured to confirm the results. The results are shown in FIG. As shown in Fig. 8, it was confirmed that the macrophages expressing CD14, CD11b, CD86 and CD45, which is a marker in blood, were 98% or more.
- the purity of the macrophages differentiated from the pluripotent stem cells produced in Example 4 is 98% or more.
- the total number of macrophages produced by the differentiation method and the differentiation inducing composition of the present invention is 5x10 8 or more, which is produced from 20 pre-differentiating stem cell colonies.
- the differentiation protocol was compared with a known known pluripotent stem cell-derived macrophage differentiation protocol (eguma K. Saito et al., Plos One, Published: April 3, 2013) and the results are shown in FIG. That is, in comparison with the existing differentiation protocol, the differentiation protocol of the present invention excluded bFGF in step 2, added IL-6 except for SCF and M-CSF in step 3, and added FL3 and GM-CSF .
- the total macrophage yield obtained with the differentiation protocol of the present invention showed a yield of 100 times higher than that of the existing differentiation protocol.
- the macrophage of the present invention and the human-derived macrophage similarity check are provided.
- RNAseq assay was confirmed for the genomic similarity of human blood cell-derived macrophages and pre-differentiating stem cell lines, and the results are shown in FIG. As shown in Fig. 12, it can be seen that the differentiated macrophages are highly similar to the human macrophages derived from human blood cells.
- influenza virus H3N2 (1 MOU) was infected with differentiated macrophages 10 ⁇ 6, and then cultured at 37 ° C for 1 to 7 days. The results are shown in FIG.
- H3N2 virus infection was observed in cells stained with Cytospin. Morula of Ana Plasma was also identified in differentiated macrophages. This result is more clearly confirmed by transmission electron microscopy, and is shown in Fig.
- Example 4 In order to confirm whether macrophages produced in Example 4 can be used as a bacterial infection study model, the following experiment was conducted. Specifically, Mycoplasma tuberculosis (Mycobacterium tuberculosis) was infected and then cultured in a 37 ° C 5% CO 2 incubator.
- Mycoplasma tuberculosis Mycobacterium tuberculosis
- the Mycobacterium tuberculosis was infected with 20,000 macrophages per concentration from MOI 1 to 20, and the results are shown in FIG. As shown in Fig. 17, it was confirmed that macrophages infected with Mycobacterium tuberculosis were increased.
- the Mycobacterium tuberculosis was fluorescently stained with GFP-inserted Mycobacterium tuberculosis, and macrophages were stained with DAPI for the detection of infection rate of macrophages.
- the infectivity of M. tuberculosis in macrophages was quantitated by confocal microscopy of GFP - expressing M. tuberculosis and DAPI - expressing macrophages.
- IMAC insulin-derived macrophage
- hMDM human blood macrophage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (12)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880040792.1A CN110770335A (zh) | 2017-12-11 | 2018-10-12 | 使用多能干细胞的免疫细胞的分化 |
US16/624,129 US20200131476A1 (en) | 2017-12-11 | 2018-10-12 | Differentiation Of Immunocytes Using Pluripotent Stem Cells |
KR1020187031277A KR102051470B1 (ko) | 2017-12-11 | 2018-10-12 | 전분화능 줄기세포를 이용한 면역세포 분화 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170169750 | 2017-12-11 | ||
KR10-2017-0169750 | 2017-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019117444A1 true WO2019117444A1 (ko) | 2019-06-20 |
Family
ID=66820501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/012065 WO2019117444A1 (ko) | 2017-12-11 | 2018-10-12 | 전분화능 줄기세포를 이용한 면역세포 분화 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20200131476A1 (ko) |
KR (1) | KR102051470B1 (ko) |
CN (1) | CN110770335A (ko) |
WO (1) | WO2019117444A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110607277A (zh) * | 2019-09-10 | 2019-12-24 | 清华大学 | 一种人类多能干细胞分化巨噬细胞的方法 |
CN115433715A (zh) * | 2022-08-15 | 2022-12-06 | 呈诺再生医学科技(北京)有限公司 | 一种诱导iPSC分化获得巨噬细胞的培养基、方法及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114209814B (zh) * | 2021-12-15 | 2024-02-23 | 南开大学 | Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途 |
KR20240054468A (ko) | 2022-10-18 | 2024-04-26 | 의료법인 성광의료재단 | 줄기세포에서 대식세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법 |
KR20240080290A (ko) | 2022-11-29 | 2024-06-07 | 의료법인 성광의료재단 | 줄기세포에서 감마델타 t세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법 |
CN116731967B (zh) * | 2023-08-16 | 2023-11-17 | 南京大学 | 从多能干细胞通过诱导分化制备巨噬细胞的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110122858A (ko) * | 2009-02-27 | 2011-11-11 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 만능 세포의 분화 |
US20140328809A1 (en) * | 2011-11-15 | 2014-11-06 | Trustees Of Dartmouth College | Methods of inducing chondrogenesis in mesenchymal stem cells using synthetic triterpenoids |
KR20150124717A (ko) * | 2014-04-29 | 2015-11-06 | 국립암센터 | Har-nds 유래 조혈줄기세포, 그 분리방법 및 용도 |
WO2016114723A1 (en) * | 2015-01-16 | 2016-07-21 | Agency For Science, Technology And Research | Differentiation of macrophages from pluripotent stem cells |
KR101738508B1 (ko) * | 2015-12-16 | 2017-05-22 | 강원대학교산학협력단 | 혈관외피세포를 이용한 무혈청조건배지 및 이를 이용한 전분화능 줄기세포로부터 조혈모세포의 분화 증진 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102329769B (zh) * | 2011-09-28 | 2013-07-31 | 浙江大学 | 一种获得造血干细胞的方法 |
WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
US11141471B2 (en) * | 2016-04-25 | 2021-10-12 | Regen BioPharma, Inc. | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells |
-
2018
- 2018-10-12 US US16/624,129 patent/US20200131476A1/en not_active Abandoned
- 2018-10-12 CN CN201880040792.1A patent/CN110770335A/zh active Pending
- 2018-10-12 WO PCT/KR2018/012065 patent/WO2019117444A1/ko active Application Filing
- 2018-10-12 KR KR1020187031277A patent/KR102051470B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110122858A (ko) * | 2009-02-27 | 2011-11-11 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 만능 세포의 분화 |
US20140328809A1 (en) * | 2011-11-15 | 2014-11-06 | Trustees Of Dartmouth College | Methods of inducing chondrogenesis in mesenchymal stem cells using synthetic triterpenoids |
KR20150124717A (ko) * | 2014-04-29 | 2015-11-06 | 국립암센터 | Har-nds 유래 조혈줄기세포, 그 분리방법 및 용도 |
WO2016114723A1 (en) * | 2015-01-16 | 2016-07-21 | Agency For Science, Technology And Research | Differentiation of macrophages from pluripotent stem cells |
KR101738508B1 (ko) * | 2015-12-16 | 2017-05-22 | 강원대학교산학협력단 | 혈관외피세포를 이용한 무혈청조건배지 및 이를 이용한 전분화능 줄기세포로부터 조혈모세포의 분화 증진 방법 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110607277A (zh) * | 2019-09-10 | 2019-12-24 | 清华大学 | 一种人类多能干细胞分化巨噬细胞的方法 |
CN110607277B (zh) * | 2019-09-10 | 2023-05-09 | 清华大学 | 一种人类多能干细胞分化巨噬细胞的方法 |
CN115433715A (zh) * | 2022-08-15 | 2022-12-06 | 呈诺再生医学科技(北京)有限公司 | 一种诱导iPSC分化获得巨噬细胞的培养基、方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20200131476A1 (en) | 2020-04-30 |
CN110770335A (zh) | 2020-02-07 |
KR102051470B1 (ko) | 2019-12-03 |
KR20190072493A (ko) | 2019-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019117444A1 (ko) | 전분화능 줄기세포를 이용한 면역세포 분화 | |
WO2022145832A1 (ko) | 역분화줄기세포(ipsc) 유래 자연 살해 세포 및 이의 용도 | |
CN109082411B (zh) | 一种通过多能干细胞分化获得具有吞噬功能的巨噬细胞的方法 | |
AU764499B2 (en) | Use of collagenase in the preparation of neural stem cell cultures | |
EP3081223A1 (en) | Method for promoting generation of stem cell-derived exosome by using thrombin | |
KR100846643B1 (ko) | 신경 세포의 제조 방법 | |
US20110263016A1 (en) | Expansion of Embryonic Stem Cells | |
WO2011025179A2 (en) | Method of inducing the differentiation of human embryonic stem cells into mesenchymal stem cells | |
CN115011553B (zh) | 一种躯干神经嵴来源骨髓间充质干细胞的制备方法及用途 | |
Esmaeilian et al. | Putative germline and pluripotent stem cells in adult mouse ovary and their in vitro differentiation potential into oocyte-like and somatic cells | |
Szade et al. | CD45− CD14+ CD34+ murine bone marrow low-adherent mesenchymal primitive cells preserve multilineage differentiation potential in long-term in vitro culture | |
WO2010013906A2 (ko) | 인간 줄기세포에서 고활성 줄기세포를 분리하는 방법 및 상기 방법에 의해 분리된 고활성 줄기 세포 | |
WO2012008733A2 (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
WO2019103528A2 (ko) | 무혈청 배지 조성물 | |
JP2023536125A (ja) | 造血細胞を分化させるシステム及び方法 | |
WO2011102680A2 (ko) | Pi3k/akt/gsk3 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 cd49f | |
CN114672455B (zh) | 一种利用多能干细胞诱导骨髓基质细胞的方法 | |
Vasyliev et al. | Large-scale expansion and characterization of human adult neural crest-derived multipotent stem cells from hair follicle for regenerative medicine applications | |
WO2022025598A1 (ko) | Smad1/5/8 활성화제를 포함하는 다능성줄기세포로부터 중간엽줄기세포로의 분화 유도용 조성물 및 그의 용도 | |
WO2018124605A1 (ko) | 기형종 형성이 억제된 전분화능 줄기세포 유래 신경 전구체구의 제조 방법 | |
AU2018251830A1 (en) | Method for obtaining differentiated cells from muscle derived progenitor cells | |
WO2019221477A1 (ko) | 전구세포 배양액 및 다층 그래핀 필름을 포함하는 줄기세포 분화 촉진용 조성물 및 이의 용도 | |
WO2010008157A2 (ko) | 줄기세포의 외배엽성 세포로의 분화 방법 | |
EP1448763A1 (en) | Characterization and isolation of subsets of human embryonic stem cells (hes) and cells associated or derived therefrom | |
WO2017039251A1 (ko) | 향상된 산후 부착형 세포 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 20187031277 Country of ref document: KR Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18889440 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18889440 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/01/2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18889440 Country of ref document: EP Kind code of ref document: A1 |